Design and Production of Arginine Deiminase-Azurin Recombinant Fusion Protein from Pseudomonas aeruginosa and its Confirmation by Western Blot
Novelty in Biomedicine,
Vol. 8 No. 2 (2020),
14 June 2020
,
Page 63-70
https://doi.org/10.22037/nbm.v1i1.26461
Abstract
Background: Pseudomonas aeruginosa is a common Gram-negative, rod-shaped bacterium that has a unique genome that allowed the bacteria to produce various enzymes and proteins. Azurin and arginine deiminase are low molecular weight proteins that produced by P. aeruginosa. These proteins can be used alone or in combination together in order to become effective in cancer therapy or inhibiting of metastasis. This study aimed to design, express and purify the Azurin and Arginine Deiminease recombinant fusion protein.Materials and Methods: The sequences of Azurin and arginine deiminase from P. aeruginosa were studied for synthesis in a pET28a vector. The recombinant plasmid was transfected into the E.coli BL-21 strain and expression was induced by isopropyl-β-D-thio galactopyranoside (IPTG). The fusion protein expression was evaluated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Purification of the recombinant product was performed by the Ni-NTA chromatography column, obtained product analysis with SDS-PAGE and Western blot technique.
Results: Cloning was confirmed by observing bands from the enzyme digestion. The protein band with a molecular weight of 65 kDa on the SDS-PAGE gel was an indication of the correct expression of the protein. The single-band of this recombinant protein was confirmed by the western blot technique.
Conclusion: In this study, due to the successful production of arginine deiminase-azurin fusion protein, and considering the separate anti-cancer properties of these compounds, which have been reported in previous studies, it is suggested that immunological assessments and effects of this fusion protein in different cancerous cell line be investigated.
- Pseudomonas aeruginosa
- Azurin
- Arginine deiminase
- Fusion Protein.
How to Cite
References
Sacha P, Wieczorek P, Hauschild T, Zórawski M, Olszańska D, Tryniszewska E. Metallo-beta-lactamases of Pseudomonas aeruginosa--a novel mechanism resistance to beta-lactam antibiotics. Folia Histochemica et cytobiologica. 2008;46(2):137-42.
Giamarellou H. Prescribing guidelines for severe Pseudomonas infections. Journal of Antimicrobial Chemotherapy. 2002;49(2):229-33.
Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrener P, Hickey MJ, et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature. 2000;406(6799):959.
Driscoll JA, Brody SL, Kollef MH. The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs. 2007;67(3):351-68.
Kipnis E, Sawa T, Wiener-Kronish J. Targeting mechanisms of Pseudomonas aeruginosa pathogenesis. Medecine et maladies infectieuses. 2006;36(2):78-91.
Galkin A, Kulakova L, Sarikaya E, Lim K, Howard A, Herzberg O. Structural insight into arginine degradation by arginine deiminase, an antibacterial and parasite drug target. Journal of Biological Chemistry. 2004;279(14):14001-8.
Murphy LM, Strange RW, Karlsson BG, Lundberg LG, Pascher T, Reinhammar B, et al. Structural characterization of azurin from Pseudomonas aeruginosa and some of its methionine-121 mutants. Biochemistry. 1993;32(8):1965-75.
Kakutani T, Watanabe H, Arima K, Beppu T. A blue protein as an inactivating factor for nitrite reductase from Alcaligenes faecalis strain S-6. The Journal of Biochemistry. 1981;89(2):463-72.
Fialho AM, Das Gupta TK, Chakrabarty AM. Designing promiscuous drugs? Look at what nature made!. Letters in Drug Design & Discovery. 2007;4(1):40-3.
Li G, Hayward IN, Jenkins BR, Rothfuss HM, Young CH, Nevalainen MT, et al. Peptidylarginine deiminase 3 (PAD3) is upregulated by prolactin stimulation of CID-9 cells and expressed in the lactating mouse mammary gland. PloS one. 2016;11(1):e0147503.
Kim RH, Coates JM, Bowles TL, McNerney GP, Sutcliffe J, Jung JU, et al. Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis. Cancer research. 2009;69(2):700-8.
Sharma A, Bala K, Husain I. Preliminary evaluation of arginine deiminase activity of indigenous bacterial strains for suitable chemotherapeutic applications. Biocatalysis and Agricultural Biotechnology. 2017;12:66-77.
Yoon CY, Shim YJ, Kim EH, Lee JH, Won NH, Kim JH, et al. Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase. International journal of cancer. 2007;120(4):897-905.
Das K, Butler GH, Kwiatkowski V, Clark Jr AD, Yadav P, Arnold E. Crystal structures of arginine deiminase with covalent reaction intermediates: implications for catalytic mechanism. Structure. 2004;12(4):657-67.
Baur H, Luethi E, Stalon V, Mercenier A, Haas D. Sequence analysis and expression of the arginine‐deiminase and carbamate‐kinase genes of Pseudomonas aeruginosa. European journal of biochemistry. 1989;179(1):53-60.
Wang Y, Li YZ. Cultivation to improve in vivo solubility of overexpressed arginine deiminases in Escherichia coli and the enzyme characteristics. BMC biotechnology. 2014;14(1):53.
Deng X, Zhang G, Zhang L, Feng Y, Li Z, Wu G, et al. Developing a novel gene-delivery vector system using the recombinant fusion protein of Pseudomonas exotoxin A and hyperthermophilic archaeal histone HPhA. PloS one. 2015;10(11):e0142558.
Faezi S, Bahrmand AR, Siadat SD, Nikokar I, Sardari S, Mahdavi M. Construction, expression, purification and characterization of secretin domain of PilQ and triple PilA-related disulfide loop peptides fusion protein from Pseudomonas aeruginosa. Iranian journal of basic medical sciences. 2017;20(5):458.
Tanom A, Farajnia S, Peerayeh SN, Majidi J. Cloning, expression and characterization of recombinant exotoxin A-flagellin fusion protein as a new vaccine candidate against Pseudomonas aeruginosa infections. Iranian biomedical journal. 2013;17(1):1.
Gholami M, Chirani AS, Razavi S, Falak R, Irajian G. Immunogenicity of a fusion protein containing PilQ and disulphide turn region of PilA from Pseudomonas aeruginosa in mice. Letters in applied microbiology. 2017;65(5):439-45.
Chen X, Zaro JL, Shen WC. Fusion protein linkers: property, design and functionality. Advanced drug delivery reviews. 2013;65(10):1357-69.
Arai R, Ueda H, Kitayama A, Kamiya N, Nagamune T. Design of the linkers which effectively separate domains of a bifunctional fusion protein. Protein engineering. 2001;14(8):529-32.
Terpe K. Overview of tag protein fusions: from molecular and biochemical fundamentals to commercial systems. Applied microbiology and biotechnology. 2003;60(5):523-33.
Andrady C, Sharma SK, Chester KA. Antibody–enzyme fusion proteins for cancer therapy. Immunotherapy. 2011;3(2):193-211.
Weidle UH, Schneider B, Georges G, Brinkmann U. Genetically engineered fusion proteins for treatment of cancer. Cancer Genomics-Proteomics. 2012;9(6):357-72.
Liao CW, Chen CA, Lee CN, Su YN, Chang MC, Syu MH, et al. Fusion protein vaccine by domains of bacterial exotoxin linked with a tumor antigen generates potent immunologic responses and antitumor effects. Cancer research. 2005;65(19):9089-98.
Robinson C, Frykberg L, Flock M, Guss B, Waller AS, Flock JI. Strangvac: A recombinant fusion protein vaccine that protects against strangles, caused by Streptococcus equi. Vaccine. 2018;36(11):1484-90.
Schmidt SR. Fusion-proteins as biopharmaceuticals–applications and challenges. Curr Opin Drug Discov Devel. 2009 Mar 1;12(2):284-95.
Chen X, Zaro JL, Shen WC. Pharmacokinetics of recombinant bifunctional fusion proteins. Expert opinion on drug metabolism & toxicology. 2012 May 1;8(5):581-95.
Punj V, Bhattacharyya S, Saint-Dic D, et al. Bacterial cupredoxin azurin as an inducer of apoptosis and regression in human breast cancer. Oncogene. 2004; 23: 2367-78.
Karlsson BG, Pascher T, Nordling M, Arvidsson RH, Lundberg LG. Expression of the blue copper protein azurin from Pseudomonas aeruginosa in Escherichia coli. FEBS letters. 1989;246(1-2):211-7.
Lee T, Chung YH, Yoon J, Min J, Choi JW. Fusion protein-based biofilm fabrication composed of recombinant azurin–myoglobin for dual-level biomemory application. Applied Surface Science. 2014 Nov 30;320:448-54.
Nishita KP, Manonmani HK. Changes in cell membrane morphology of colon cancer cells (HCT116) after treatment with azurin derived hexapeptide 4 by AFM and STEM. International Journal of Innovative Research in Science, Engineering and Technology. 2015;4(11):11550-7.
Lee T, Min J, Hirakawa H, Nagamune T, Choi JW. Fusion protein bilayer fabrication composed of recombinant azurin/cytochrome P450 by the sortase-mediated ligation method. Colloids and Surfaces B: Biointerfaces. 2014;120:215-21.
Mercenier A, Stalon V, Simon JP, Haas D. Mapping of the arginine deiminase gene in Pseudomonas aeruginosa. Journal of bacteriology. 1982;149(2):787-8.
Mercenier A, Simon JP, Haas D, Stalon V. Catabolism of L-arginine by Pseudomonas aeruginosa. Microbiology. 1980;116(2):381-9.
Kundu M, Thomas J, Fialho AM, Kwan JM, Moreira LM, Mahfouz M, et al. The anticancer activity of the N-terminal CARD-like domain of arginine deiminase (ADI) from Pseudomonas aeruginosa. Letters in Drug Design & Discovery. 2009;6(6):403-12.
Ott PA, Carvajal RD, Pandit-Taskar N, Jungbluth AA, Hoffman EW, Wu BW, et al. Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Investigational new drugs. 2013;31(2):425-34.
El‐Sayed AS, Hassan MN, Nada HM. Purification, immobilization, and biochemical characterization of l‐arginine deiminase from thermophilic Aspergillus fumigatus KJ 434941: Anticancer activity in vitro. Biotechnology progress. 2015;31(2):396-405.
Miraki-Moud F, Ghazaly E, Ariza-McNaughton L, Hodby KA, Clear A, Anjos-Afonso F, et al. Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo. Blood. 2015;125(26):4060-8.
Wong BL, Wai NF, Kwok SY, Leung YC. Inventors; Vision Global Holdings Ltd, assignee. Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein. United States patent US 9,803,185. 2017 Oct 31.
Stevens RC. Design of high-throughput methods of protein production for structural biology. Structure. 2000;8(9):177-85.
Bornhorst JA, Falke JJ. [16] Purification of proteins using polyhistidine affinity tags. InMethods in enzymology. Academic Press. 2000;326:245-54.
- Abstract Viewed: 620 times
- Remote Downloaded: 0 times
- PDF Downloaded: 261 times